ABBVIE INC (1ABBV.MI) Stock Price, Forecast & Analysis
Europe - Euronext Milan - BIT:1ABBV - US00287Y1091 - Common Stock
1ABBV.MI Key Statistics, Chart & Performance
The current stock price of 1ABBV.MI is 189.6 EUR. In the past month the price decreased by -3.5%.
1ABBV.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 67.86 | 44.21B | ||
| ARGX.BR | ARGENX SE | 65.18 | 42.46B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.19B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.91B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.03B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.83B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.83B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 827.38M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| IVA.PA | INVENTIVA SA | N/A | 744.97M | ||
| PHIL.MI | PHILOGEN SPA | 19.96 | 665.21M |
Related stock screener links
About 1ABBV.MI
Company Profile
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
Company Info
ABBVIE INC
1 N Waukegan Rd
North Chicago ILLINOIS US
Employees: 55000
Phone: 18479327900
ABBVIE INC / 1ABBV.MI FAQ
Can you describe the business of ABBVIE INC?
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. The company is headquartered in North Chicago, Illinois and currently employs 55,000 full-time employees. The company went IPO on 2013-01-02. The firm is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Its Immunology products include rheumatology, dermatology and gastroenterology. Its Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere, and Epkinly. The Company’s Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Its Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and Other eye care. Its Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its Venclexta is a B-cell lymphoma 2 (BCL-2) inhibitor used to treat blood cancers.
What is the stock price of ABBVIE INC today?
The current stock price of 1ABBV.MI is 189.6 EUR. The price decreased by -6.6% in the last trading session.
Does 1ABBV stock pay dividends?
ABBVIE INC (1ABBV.MI) has a dividend yield of 3.09%. The yearly dividend amount is currently 5.32.
How is the ChartMill rating for ABBVIE INC?
1ABBV.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Can you provide the PE ratio for 1ABBV stock?
The PE ratio for ABBVIE INC (1ABBV.MI) is 23.52. This is based on the reported non-GAAP earnings per share of 8.06 and the current share price of 189.6 EUR.
When does ABBVIE INC (1ABBV.MI) report earnings?
ABBVIE INC (1ABBV.MI) will report earnings on 2026-01-29, after the market close.
Can you provide the ownership details for 1ABBV stock?
You can find the ownership structure of ABBVIE INC (1ABBV.MI) on the Ownership tab.
1ABBV.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1ABBV.MI.
1ABBV.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1ABBV.MI. There are concerns on the financial health of 1ABBV.MI while its profitability can be described as average.
1ABBV.MI Financial Highlights
Over the last trailing twelve months 1ABBV.MI reported a non-GAAP Earnings per Share(EPS) of 8.06. The EPS decreased by -12.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 3.94% | ||
| ROA | 1.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
1ABBV.MI Forecast & Estimates
38 analysts have analysed 1ABBV.MI and the average price target is 213.47 EUR. This implies a price increase of 12.59% is expected in the next year compared to the current price of 189.6.
For the next year, analysts expect an EPS growth of 7.28% and a revenue growth 8.73% for 1ABBV.MI